Coalition Commends Bipartisan Group of Lawmakers for Commitment to Cracking
Down on Big Pharma’s Egregious Abuse of the U.S. Patent System





 





CSRXP STATEMENT ON U.S. SENATE REINTRODUCTION OF THE ETHIC ACT

Coalition Commends Bipartisan Group of Lawmakers for Commitment to Cracking
Down on Big Pharma’s Egregious Abuse of the U.S. Patent System



Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) issued the
following statement on Wednesday on thereintroduction
<[link removed]>
of the “Eliminating Thickets to Improve Competition (ETHIC) Act” in the U.S.
Senate. A U.S. House companion of the bill wasintroduced
<[link removed]> in May.



“CSRxP commends U.S. Senators Welch (D-VT), Hawley (R-MO), Klobuchar (D-MN),
U.S. Representative Jodey Arrington (R-TX-19) and all the sponsors of the ETHIC
Act for their commitment to holding Big Pharma accountable for egregious abuse
of the patent system that keeps prescription drug prices high for American
patients,” said CSRxP executive director Lauren Aronson. “Anti-competitive
tactics, like patent thicketing, enable Big Pharma to extend monopoly pricing
on blockbuster products, costing patients, taxpayers and the U.S. health care
system billions of dollars each year. Fostering greater competition by cracking
down on Big Pharma’s patent abuse will bring more affordable alternatives to
the market earlier and help lower prices for patients.”



Read more about Big Pharma’s patent abuse HERE
<[link removed]>.



Read more on bipartisan, market-based solutions to hold Big Pharma accountable
HERE <[link removed]>.



###

































Copyright © 2019 Campaign for Sustainable Rx Pricing
Our address is 1341 G St NW, #1100, Washington, DC xxxxxx


This email was sent to [email protected]. To unsubscribe please click
here.
<[link removed]->